Roche(US:RHHBY) Jing Ji Guan Cha Wang·2026-02-13 17:11Core Viewpoint - The stock price of ShuoDi Bio has been on a continuous decline despite recent positive developments, indicating a disconnect between market performance and company fundamentals [1][2][4]. Stock Performance - As of February 13, 2026, ShuoDi Bio's stock closed at $71.25, down 1.10% for the day, with a cumulative decline of 4.90% over the past five days and a price fluctuation of 14.82%, reaching a low of $70.05 [1]. - The trading volume showed significant variation, with a peak of $64.05 million on February 12 (turnover rate of 1.24%) and a drop to $21.96 million on February 13 (volume ratio of 1.08) [1]. - The biotechnology sector rose by 1.84%, but ShuoDi Bio's performance lagged behind the broader market, which saw the Nasdaq index decline by 1.54% [1]. Recent Events - On December 30, 2025, ShuoDi Bio entered a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and the right to earn low single-digit royalties on future sales of Genentech's oral GLP-1 drug CT-996 [2]. - This partnership does not restrict the company's core pipeline development and provides non-dilutive funding support, yet the stock price has not reflected this positive news [2]. Financial Analysis - For the third quarter of 2025, ShuoDi Bio reported zero revenue and a net loss of $65.8 million, with a return on equity (ROE) of -25.31%, indicating ongoing pressure on short-term profitability due to R&D investments [3]. - The company has a debt-to-asset ratio of 7.47% and a current ratio of 14.15%, suggesting a solid financial structure despite significant profitability gaps [3]. Institutional Perspectives - Multiple brokerages remain optimistic about ShuoDi Bio's long-term value, primarily due to the cash flow potential from the patent collaboration and the scarcity of the oral GLP-1 pipeline [4]. - However, short-term stock performance is constrained by sector rotation, technical corrections, and market concerns regarding increased competition in the GLP-1 space, leading to significant funding divergence [4].